Catalyst Pharmaceuticals (CPRX) Competitors

Ascendis Pharma A/S (NASDAQ:ASND) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings.

Does the media favor ASND or CPRX?

In the previous week, Catalyst Pharmaceuticals had 9 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 18 mentions for Catalyst Pharmaceuticals and 9 mentions for Ascendis Pharma A/S. Catalyst Pharmaceuticals' average media sentiment score of 1.07 beat Ascendis Pharma A/S's score of 0.84 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Catalyst Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ASND or CPRX more profitable?

Catalyst Pharmaceuticals has a net margin of 31.01% compared to Ascendis Pharma A/S's net margin of -104.54%. Catalyst Pharmaceuticals' return on equity of 40.79% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	-104.54%	N/A	-39.23%
Catalyst Pharmaceuticals	31.01%	40.79%	34.87%

Do analysts prefer ASND or CPRX?

Ascendis Pharma A/S presently has a consensus target price of $204.64, indicating a potential upside of 27.08%. Catalyst Pharmaceuticals has a consensus target price of $32.29, indicating a potential upside of 25.53%. Given Ascendis Pharma A/S's higher probable upside, equities research analysts clearly believe Ascendis Pharma A/S is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93
Catalyst Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

Do institutionals and insiders hold more shares of ASND or CPRX?

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by insiders. Comparatively, 11.0% of Catalyst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Which has more risk and volatility, ASND or CPRX?

Ascendis Pharma A/S has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Which has stronger earnings & valuation, ASND or CPRX?

Catalyst Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$363.64M	26.88	-$409.12M	-$7.10	-22.68
Catalyst Pharmaceuticals	$491.73M	6.35	$71.41M	$1.31	19.63

Does the MarketBeat Community favor ASND or CPRX?

Catalyst Pharmaceuticals received 57 more outperform votes than Ascendis Pharma A/S when rated by MarketBeat users. Likewise, 75.11% of users gave Catalyst Pharmaceuticals an outperform vote while only 66.82% of users gave Ascendis Pharma A/S an outperform vote.

Company	Underperform	Outperform
Ascendis Pharma A/S	Outperform Votes 447 66.82%	Underperform Votes 222 33.18%
Catalyst Pharmaceuticals	Outperform Votes 504 75.11%	Underperform Votes 167 24.89%

Summary

Catalyst Pharmaceuticals beats Ascendis Pharma A/S on 15 of the 19 factors compared between the two stocks.